[go: up one dir, main page]

ATE213020T1 - Klonierung und expression von biologisch aktiver alpha-galaktosidase a - Google Patents

Klonierung und expression von biologisch aktiver alpha-galaktosidase a

Info

Publication number
ATE213020T1
ATE213020T1 AT94902448T AT94902448T ATE213020T1 AT E213020 T1 ATE213020 T1 AT E213020T1 AT 94902448 T AT94902448 T AT 94902448T AT 94902448 T AT94902448 T AT 94902448T AT E213020 T1 ATE213020 T1 AT E213020T1
Authority
AT
Austria
Prior art keywords
galactosidase
biologically active
mammalian cell
acid residues
sialic acid
Prior art date
Application number
AT94902448T
Other languages
English (en)
Inventor
Robert J Desnick
David F Bishop
Yiannis A Ioannou
Original Assignee
Sinai School Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25529958&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE213020(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sinai School Medicine filed Critical Sinai School Medicine
Application granted granted Critical
Publication of ATE213020T1 publication Critical patent/ATE213020T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/18—Erythrocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01049—Alpha-N-acetylgalactosaminidase (3.2.1.49)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT94902448T 1992-11-30 1993-11-30 Klonierung und expression von biologisch aktiver alpha-galaktosidase a ATE213020T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/983,451 US5401650A (en) 1990-10-24 1992-11-30 Cloning and expression of biologically active α-galactosidase A
PCT/US1993/011539 WO1994012628A1 (en) 1992-11-30 1993-11-30 Cloning and expression of biologically active alpha-galactosidase a

Publications (1)

Publication Number Publication Date
ATE213020T1 true ATE213020T1 (de) 2002-02-15

Family

ID=25529958

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07022356T ATE464386T1 (de) 1992-11-30 1993-11-30 Verfahren zur herstellung sekretierter proteine
AT94902448T ATE213020T1 (de) 1992-11-30 1993-11-30 Klonierung und expression von biologisch aktiver alpha-galaktosidase a

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT07022356T ATE464386T1 (de) 1992-11-30 1993-11-30 Verfahren zur herstellung sekretierter proteine

Country Status (14)

Country Link
US (2) US5401650A (de)
EP (4) EP1020528A3 (de)
JP (2) JP4005629B2 (de)
AT (2) ATE464386T1 (de)
AU (1) AU691795B2 (de)
CA (1) CA2150555C (de)
DE (3) DE69331550T3 (de)
DK (3) DK0670896T3 (de)
ES (3) ES2431293T3 (de)
IL (4) IL220131A0 (de)
LU (2) LU91703I2 (de)
PT (3) PT670896E (de)
SE (1) SE2210947T5 (de)
WO (1) WO1994012628A1 (de)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040064855A1 (en) * 1988-02-26 2004-04-01 Large Scale Biology Corporation Production of lysosomal enzymes in plants by transient expression
US6846968B1 (en) * 1988-02-26 2005-01-25 Large Scale Biology Corporation Production of lysosomal enzymes in plants by transient expression
US5179023A (en) * 1989-03-24 1993-01-12 Research Corporation Technologies, Inc. Recombinant α-galactosidase a therapy for Fabry disease
CA2159083C (en) * 1993-03-26 2002-07-02 Alex Zhu Recombinant .alpha.-n-acetylgalactosaminidase enzyme and cdna encoding said enzyme
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
AU2012227349B2 (en) * 1996-09-13 2015-12-24 Shire Human Genetic Therapies, Inc. Therapy for alpha-galactosidase A deficiency
RU2179034C2 (ru) * 1996-09-13 2002-02-10 Транскариотик Терапиз, Инк. ЛЕЧЕНИЕ В СЛУЧАЕ ДЕФИЦИТА α-ГАЛАКТОЗИДАЗЫ А
US6083725A (en) * 1996-09-13 2000-07-04 Transkaryotic Therapies, Inc. Tranfected human cells expressing human α-galactosidase A protein
IL155588A0 (en) * 2003-04-27 2003-11-23 Metabogal Ltd Methods for expression of enzymatically active recombinant lysosomal enzymes in transgenic plant root cells and vectors used thereby
US6455037B1 (en) * 1996-11-01 2002-09-24 Mount Sinai School Of Medicine Of The City University Of New York Cells expressing an αgala nucleic acid and methods of xenotransplantation
US6210666B1 (en) 1997-10-21 2001-04-03 Orphan Medical, Inc. Truncated α-galactosidase A to treat fabry disease
DE69835367T2 (de) * 1997-10-29 2007-08-02 Genzyme Corp., Framingham Gentherapie für gaucher-krankheit
EP1658857A1 (de) * 1997-10-29 2006-05-24 Genzyme Corporation Zusammensetzungen und Methoden zum Behandlung von lysosomalen Lagerungskrankheit
JP4493854B2 (ja) * 1998-12-23 2010-06-30 リジェネロン・ファーマシューティカルズ・インコーポレイテッド リガンドの生物学的活性を増強する方法
AU2016250357B2 (en) * 1999-03-11 2018-11-01 Shire Human Genetic Therapies, Inc. Treatment of alpha-Galactosidase A deficiency
AU2012241170B2 (en) * 1999-03-11 2016-07-28 Shire Human Genetic Therapies, Inc. Treatment of alpha-Galactosidase A deficiency
US6537785B1 (en) 1999-09-14 2003-03-25 Genzyme Glycobiology Research Institute, Inc. Methods of treating lysosomal storage diseases
US6770468B1 (en) 1999-09-14 2004-08-03 Genzyme Glycobiology Research Institute, Inc. Phosphodiester-α-GlcNAcase of the lysosomal targeting pathway
CN1312383A (zh) * 2000-03-07 2001-09-12 上海博德基因开发有限公司 一种新的多肽——人alpha－半乳糖苷酶A－11和编码这种多肽的多核苷酸
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US7629309B2 (en) * 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
ES2300439T3 (es) * 2001-04-30 2008-06-16 Zystor Therapeutics , Inc. Reconocimiento subcelular de proteinas terapeuticas.
US20040005309A1 (en) * 2002-05-29 2004-01-08 Symbiontics, Inc. Targeted therapeutic proteins
JP4742191B2 (ja) * 2001-06-14 2011-08-10 独立行政法人産業技術総合研究所 糖蛋白質およびその製造方法
US7767415B2 (en) 2001-09-25 2010-08-03 Velico Medical, Inc. Compositions and methods for modifying blood cell carbohydrates
CA2462930C (en) 2001-10-10 2012-07-10 Shawn De Frees Remodeling and glycoconjugation of peptides
WO2004099231A2 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US20030072761A1 (en) * 2001-10-16 2003-04-17 Lebowitz Jonathan Methods and compositions for targeting proteins across the blood brain barrier
US20030124652A1 (en) * 2001-12-21 2003-07-03 Novazyme Pharmaceuticals, Inc. Methods of producing high mannose glycoproteins in complex carbohydrate deficient cells
US6800472B2 (en) * 2001-12-21 2004-10-05 Genzyme Glycobiology Research Institute, Inc. Expression of lysosomal hydrolase in cells expressing pro-N-acetylglucosamine-1-phosphodiester α-N-acetyl glucosimanidase
US6905856B2 (en) * 2001-12-21 2005-06-14 Genzyme Glycobiology Research Institute, Inc. Soluble GlcNAc phosphotransferase
US7658916B2 (en) * 2002-04-05 2010-02-09 Genzyme Corporation Methods of enhancing lysosomal storage disease therapy by modulation of cell surface receptor density
EP2361631A1 (de) 2002-04-25 2011-08-31 Shire Human Genetic Therapies, Inc. Behandlung der alpha-Galactosidase A-Defizienz
SI2444102T1 (sl) 2003-01-31 2015-08-31 Mount Sinai School Of Medicine Of New York University Kombinirana terapija za zdravljenje motenj pomanjkanja proteina
US7951557B2 (en) 2003-04-27 2011-05-31 Protalix Ltd. Human lysosomal proteins from plant cell culture
US7741340B2 (en) * 2003-11-12 2010-06-22 Amicus Therapeutics, Inc. Hydroxy piperidine derivatives to treat gaucher disease
CA2553955C (en) * 2004-02-10 2012-08-28 Zystor Therapeutics, Inc. Acid alpha-glucosidase and fragments thereof
US8889127B2 (en) * 2004-07-01 2014-11-18 Icahn School Of Medicine At Mount Sinai Targeted protein replacement for the treatment of lysosomal storage disorders
WO2007008220A2 (en) * 2004-08-05 2007-01-18 Baylor Research Institute Gene or drug delivery system
AU2006247065B8 (en) 2005-05-17 2012-07-12 Amicus Therapeutics, Inc. A method for the treatment of Pompe disease using 1-deoxynojirimycin derivatives
US8470318B2 (en) 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
JP4368925B2 (ja) 2005-11-18 2009-11-18 財団法人 東京都医学研究機構 基質特異性を変換した新規高機能酵素
EP2361613B1 (de) 2006-02-07 2020-08-12 Shire Human Genetic Therapies, Inc. Stabilisierte Proteinzusammensetzungen mit einem freien Thiolanteil
GB0606190D0 (en) 2006-03-28 2006-05-10 Isis Innovation Construct
AU2007235413B2 (en) 2006-04-05 2012-08-02 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
JP2010509344A (ja) * 2006-11-13 2010-03-25 ザイストール セラピューティクス， インコーポレイテッド ポンペ病を治療するための方法
RU2468076C2 (ru) 2007-05-07 2012-11-27 Проталикс Лтд. Одноразовое устройство для культивирования и сбора растительной ткани и/или клеток, способ и система культивирования и сбора растительной ткани и/или растительных клеток
AU2008290217B2 (en) * 2007-08-20 2013-09-05 Protalix Ltd. Saccharide-containing protein conjugates and uses thereof
AU2009214648B2 (en) * 2008-02-12 2014-11-13 Amicus Therapeutics, Inc. Method to predict response to pharmacological chaperone treatment of diseases
MX2010011598A (es) 2008-04-22 2010-12-15 Univ Rockefeller Metodos para identificar compuestos anti-inflamatorios.
EP3187508A1 (de) 2008-05-07 2017-07-05 BioMarin Pharmaceutical Inc. Auf lysosomen gerichtete peptide und verwendungen davon
US8592555B2 (en) * 2008-08-11 2013-11-26 Emd Millipore Corporation Immunoglobulin-binding proteins with improved specificity
KR20110076906A (ko) * 2008-09-30 2011-07-06 아보트 러보러터리즈 개선된 ｒｎａ 디스플레이 방법
SG195555A1 (en) 2008-12-24 2013-12-30 Emd Millipore Corp Caustic stable chromatography ligands
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
EP2475376B1 (de) 2009-06-17 2016-03-30 BioMarin Pharmaceutical Inc. Formulierungen für lysosomale enzyme
PL3354277T3 (pl) 2009-07-28 2021-12-13 Takeda Pharmaceutical Company Limited Kompozycje i sposoby leczenia choroby gauchera
US9194011B2 (en) 2009-11-17 2015-11-24 Protalix Ltd. Stabilized alpha-galactosidase and uses thereof
WO2011108451A1 (ja) * 2010-03-01 2011-09-09 日本ケミカルリサーチ株式会社 遺伝子ノックアウト細胞を用いた組換え体リソソーム酵素の製造方法
ES2606532T3 (es) 2010-03-02 2017-03-24 Protalix Ltd. Alfa-galactosidasa estabilizada y usos de la misma
US20120328589A1 (en) 2010-03-02 2012-12-27 Ilya Ruderfer Glucocerebrosidase multimers and uses thereof
EP2595651B1 (de) 2010-07-19 2017-03-29 Shire Human Genetic Therapies, Inc. Kodonoptimierte zelllinie für den mannoserezeptor-c vom typ 1 (mrc1) und anwendungen davon
US8679478B2 (en) 2010-10-04 2014-03-25 Duke University Methods of lysosomal storage disease therapy
EP2627349B1 (de) 2010-10-15 2016-02-03 The Trustees of Columbia University in the City of New York Gene und zugehörige proteine im zusammenhang mit adipositas sowie verwendungen davon
HUE045869T2 (hu) 2010-11-02 2020-01-28 Univ Columbia Módszerek hajhullásos rendellenességek kezelésére
KR101883803B1 (ko) 2011-01-20 2018-07-31 프로탈릭스 리미티드 식물 및 식물 세포에서 알파-갈락토시다제의 발현용 핵산 작제물
SG186552A1 (en) 2011-06-08 2013-01-30 Emd Millipore Corp Chromatography matrices including novel staphylococcus aureus protein a based ligands
HUE051021T2 (hu) 2011-09-07 2021-01-28 Sinai School Medicine Ceramidáz és sejtek differenciálódása
CN104519905A (zh) 2012-03-02 2015-04-15 夏尔人类遗传性治疗公司 用于治疗iii型戈谢病的组合物和方法
MX349992B (es) 2012-03-07 2017-08-22 Amicus Therapeutics Inc Composiciones de alta concentracion de alfa-glucosidasa para el tratamiento de la enfermedad de pompe.
WO2013139861A1 (en) 2012-03-20 2013-09-26 Luc Montagnier Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
DK2830662T3 (da) 2012-03-29 2019-01-02 Univ Columbia Fremgangsmåder til behandlng af hårtabsforstyrrelser
WO2013181530A1 (en) 2012-06-01 2013-12-05 Icahn School Of Medicine At Mount Sinai Ceramide levels in the treatment and prevention of infections
WO2014016873A1 (en) * 2012-07-26 2014-01-30 Jcr Pharmaceuticals Co., Ltd. Method for production of recombinant human alpha-galactosidase a
JP6226435B2 (ja) * 2012-07-26 2017-11-08 Ｊｃｒファーマ株式会社 組換えヒトα−ガラクトシダーゼＡの製造方法
EP2968479B1 (de) 2013-03-14 2019-07-17 Icahn School of Medicine at Mount Sinai Therapeutische säure-ceramidase-zusammensetzungen und verfahren zur herstellung und verwendung davon
US9889203B2 (en) * 2013-03-15 2018-02-13 Amicus Therapeutics, Inc. Chemical crosslinkers
KR102369211B1 (ko) * 2013-09-16 2022-03-03 젠자임 코포레이션 세포 배양물을 가공하는 방법 및 시스템
TWI642782B (zh) * 2013-10-23 2018-12-01 健臻公司 重組醣蛋白及其用途
US9682123B2 (en) 2013-12-20 2017-06-20 The Trustees Of Columbia University In The City Of New York Methods of treating metabolic disease
SG10202003753PA (en) 2014-09-30 2020-05-28 Amicus Therapeutics Inc Highly potent acid alpha-glucosidase with enhanced carbohydrates
WO2016116966A1 (en) 2015-01-22 2016-07-28 Jcr Pharmaceuticals Co., Ltd. Method for purification of recombinant human alpha-galactosidase a from material containing contaminant host cell proteins
US9981021B1 (en) 2015-04-09 2018-05-29 Kinetiq, Inc. Subcutaneous therapeutic enzyme formulations, uses, and methods for generating thereof
AU2016321298A1 (en) 2015-09-09 2018-03-29 The Trustees Of Columbia University In The City Of New York Reduction of ER-MAM localized APP-C99 and methods of treating Alzheimer's Disease
WO2017049157A1 (en) 2015-09-18 2017-03-23 Duke University Methods and compositions for the treatment of steatosis-associated disorders
WO2017117407A1 (en) 2015-12-30 2017-07-06 Amicus Therapeutics, Inc. Augmented acid alpha-glucosidase for the treatment of pompe disease
BR112018069965A2 (pt) 2016-03-30 2019-01-29 Amicus Therapeutics Inc formulações compreendendo alfa-glucosidase ácida recombinante
BR112018070189A2 (pt) 2016-03-30 2019-02-19 Amicus Therapeutics, Inc. método para seleção de proteínas recombinantes ricas em m6p
NL2017294B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Natural cryptic exon removal by pairs of antisense oligonucleotides.
US11154591B2 (en) 2016-10-14 2021-10-26 The Trustees Of Columbia University In The City Of New York Methods of treating alcohol abuse disorder
CN119113091A (zh) 2017-05-15 2024-12-13 阿米库斯治疗学公司 重组人类酸性α-葡萄糖苷酶
RU2698460C1 (ru) * 2019-03-28 2019-08-27 Общество с ограниченной ответственностью "Международный Биотехнологический Центр "Генериум" Способ получения рекомбинантной в-1,4-галактозидазы bgaa из streptococcus pneumoniae
EP3996696A1 (de) 2019-07-09 2022-05-18 Genethon Behandlung von glykogenspeichererkrankung (gsd)
CN112795583A (zh) * 2020-11-16 2021-05-14 上海大学 重组唾液酸外切酶的制备方法、表达基因、重组表达载体及构建方法
CA3217356A1 (en) * 2021-04-20 2022-10-27 Walking Fish Therapeutics, Inc. Engineering b cell-based protein factories to treat serious diseases

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH585793A5 (de) * 1974-02-01 1977-03-15 Nestle Sa
JPS5322158B2 (de) * 1974-05-02 1978-07-06
IT1130242B (it) * 1980-02-01 1986-06-11 Anic Spa Procedimento per la produzione dell'enzima alfa-galattosidasi e per l'idrolisi del raffinosio mediante l'impiego dell'enzima stesso
US4925796A (en) * 1986-03-07 1990-05-15 Massachusetts Institute Of Technology Method for enhancing glycoprotein stability
US5047335A (en) * 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
EP0463109A4 (en) * 1989-03-24 1992-11-19 Research Corporation Technologies, Inc. Recombinant alpha-galactosidase, a therapy for fabry disease
US5032519A (en) * 1989-10-24 1991-07-16 The Regents Of The Univ. Of California Method for producing secretable glycosyltransferases and other Golgi processing enzymes
DE4028800A1 (de) * 1990-09-11 1992-03-12 Behringwerke Ag Gentechnische sialylierung von glykoproteinen
US5382524A (en) * 1990-10-24 1995-01-17 The Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of biologically active α-n-acetylgalactosaminidase

Also Published As

Publication number Publication date
JP2004121260A (ja) 2004-04-22
EP1942189B1 (de) 2010-04-14
LU91703I2 (fr) 2010-08-24
DE69331550T2 (de) 2002-09-26
ES2168101T3 (es) 2002-06-01
CA2150555A1 (en) 1994-06-09
DK2210947T3 (da) 2013-10-07
IL220131A0 (en) 2012-07-31
PT1942189E (pt) 2010-05-28
DE69331550D1 (de) 2002-03-21
DE69334327D1 (de) 2010-05-27
EP2210947B1 (de) 2013-07-17
EP2210947A2 (de) 2010-07-28
IL107814A0 (en) 1994-02-27
IL220132A0 (en) 2012-07-31
DK1942189T3 (da) 2010-06-07
EP1020528A3 (de) 2000-10-04
ES2431293T3 (es) 2013-11-25
IL107814A (en) 2012-12-31
WO1994012628A1 (en) 1994-06-09
CA2150555C (en) 2010-11-02
IL200005A (en) 2013-09-30
PT2210947E (pt) 2013-10-23
US5401650A (en) 1995-03-28
DE69331550T3 (de) 2006-06-29
JP4005629B2 (ja) 2007-11-07
JPH08503615A (ja) 1996-04-23
EP0670896A1 (de) 1995-09-13
EP1020528A2 (de) 2000-07-19
ATE464386T1 (de) 2010-04-15
ES2344431T3 (es) 2010-08-26
LU91704I2 (fr) 2010-08-24
SE2210947T5 (de) 2015-02-03
JP3598302B2 (ja) 2004-12-08
EP0670896B1 (de) 2002-02-06
AU691795B2 (en) 1998-05-28
EP0670896B2 (de) 2005-04-27
US5580757A (en) 1996-12-03
DK0670896T3 (da) 2002-05-27
EP0670896A4 (de) 1997-08-20
EP1942189A2 (de) 2008-07-09
AU5681794A (en) 1994-06-22
PT670896E (pt) 2002-07-31
EP1942189A3 (de) 2008-09-10
DE122010000028I1 (de) 2010-08-12
EP2210947A3 (de) 2010-10-06
ES2168101T5 (es) 2005-10-16

Similar Documents

Publication Publication Date Title
ATE213020T1 (de) Klonierung und expression von biologisch aktiver alpha-galaktosidase a
PT787180E (pt) Meio de cultura de celulas embrionarias totipotentes avicolas desprovidas de acido retinoico activo
GR3032790T3 (en) Materials and methods for hypersecretion of amino acids
AU2443488A (en) Dna-molecules coding for fmdh control regions and structured gene for a protein having fmdh-activity and their uses
DE59409542D1 (de) Neue Mikroorganismen, deren Verwendung und Verfahren zur Herstellung von L-Alpha-Aminosäuren
PT92603A (pt) Processo de producao de factor de crescimento transformante, quimerico,beta
GB2196636B (en) Production of proteins by cell culture
KR920004570A (ko) 사람 mk 단백질을 암호하는 유전자, 이를 포함하는 발현 벡터 및 숙주 세포, mk단백질의 생산 방법 및 사용방법
ATE70302T1 (de) Verfahren zur expression von alpha-1-antitrypsin in bakterien und dessen verwendung in therapeutischen zusammensetzungen sowie vektoren und bakterien fuer ein solches verfahren und deren herstellung.
BR0309401A (pt) polinucleotìdeo isolado, vetor de expressão, célula cultivada, método para produzir polipeptìdeos, e um anticorpo para um polipeptìdeo, e, anticorpo
KR910006483A (ko) 재조합 아프로티닌 변이체, 균질하게 프로세싱된 아프로티닌 변이체의 미생물을 이용한 유전공학적 제조 방법 및 그의 치료 용도
ATE30246T1 (de) Verfahren zur herstellung reifer proteine aus schmelzproteinen hergestellt in pro- oder eukaryotischen zellen.
ES2088911T3 (es) Gen de la proteasa i de achromobacter y el producto de este gen.
ATE109827T1 (de) Verfahren zur herstellung von peptiden, dazu zu verwendendes rekombinantes plasmid und mit diesem plasmid transformierte myelomzellen.
FI945877A0 (fi) Menetelmä proteiini C:n tuottamiseksi
AU1090688A (en) Synthetic porcine growth hormone
ATE67243T1 (de) Verfahren zur herstellung von insulinaehnlichem wachstumsfaktor i (igf-i) und plasmid zu dessen herstellung.
DE60335602D1 (de) Rekombinante Desoxyribonuclease I aus Rinder-Pankreas mit hoher spezifischer Aktivität
DE69832709D1 (de) Verfahren zur herstellung von fremden proteinen
KR950018453A (ko) 콜라게네이즈 인지부위를 가진 재조합 인간 성장 호르몬
DK0635061T3 (da) Fremgangsmåde til begrænsning af genetisk manipulerede organismers overlevelse i deres miljø
DE58909205D1 (de) Expressionsvektor und Verfahren zur regulierbaren Herstellung von Proteinen in Eukaryonten.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0670896

Country of ref document: EP

RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties